IMpower151: Phase III study of atezolizumab + bevacizumab + chemotherapy in first-line metastatic nonsquamous NSCLC
The Phase III IMpower151 (NCT04194203) study was conducted in China to evaluate the efficacy and safety of atezolizumab, bevacizumab, carboplatin, plus paclitaxel or pemetrexed (ABCPem/Pac) vs BCPem/Pac, as 1L treatment for metastatic non-squamous NSCLC. This presentation reports on results from IMpower151.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.